CB-5945 + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Opioid-Induced Constipation

Conditions

Opioid-Induced Constipation

Trial Timeline

Oct 12, 2012 → Jul 21, 2014

NCT ID

NCT01696643

About CB-5945 + Placebo

CB-5945 + Placebo is a phase 3 stage product being developed by Merck for Opioid-Induced Constipation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01696643. Target conditions include Opioid-Induced Constipation.

What happened to similar drugs?

4 of 20 similar drugs in Opioid-Induced Constipation were approved

Approved (4) Terminated (7) Active (10)

✅Naldemedine + PlaceboShionogiApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

🔄Naldemedine + PlaceboShionogiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01901341	Phase 3	Terminated	Jul 2, 2013	Feb 13, 2014	Opioid-Induced Constipation
NCT01901302	Phase 3	Terminated	May 20, 2013	Feb 13, 2014	Opioid-Induced Constipation
NCT01901328	Phase 3	Terminated	Apr 7, 2013	Feb 13, 2014	Opioid-Induced Constipation
NCT01696643	Phase 3	Terminated	Oct 12, 2012	Jul 21, 2014	Opioid-Induced Constipation

Competing Products

20 competing products in Opioid-Induced Constipation

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naloxegol	Kyowa Kirin	Pre-clinical	26
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
Naloxegol + Placebo Oral Capsule	AstraZeneca	Phase 2	27
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Methylnaltrexone bromide + Placebo	Pfizer	Phase 2	35
ALKS 37 + Placebo	Alkermes	Phase 2	32